Citadel Advisors’s InMed Pharmaceuticals INM Stock Holding History

Citadel Advisors’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.3K	Buy	+46,973	New	+$44.3K	﹤0.01%	12568
2024 Q4	–	Sell	-2,833	Closed	-$13.3K	–	14918
2024 Q3	$13.3K	Buy	2,833 +2,228	+368%	+$11.4K	﹤0.01%	13067
2024 Q2	$3.21K	Sell	605 -31	-5%	-$177	﹤0.01%	13614
2024 Q1	$4.48K	Sell	636 -1,064	-63%	-$7.82K	﹤0.01%	13813
2023 Q4	$14.1K	Buy	+1,700	New	+$16.5K	﹤0.01%	12892
2022 Q3	–	Sell	-26	Closed	-$6K	–	13085
2022 Q2	$6K	Buy	+26	New	+$9.95K	﹤0.01%	12664
2022 Q1	–	Sell	-22	Closed	-$14K	–	14069
2021 Q4	$14K	Sell	22 -14	-39%	-$10.8K	﹤0.01%	13636
2021 Q3	$31K	Buy	36 +5	+16%	+$5.96K	﹤0.01%	13560
2021 Q2	$49K	Sell	31 -3	-9%	-$4.64K	﹤0.01%	13345
2021 Q1	$57K	Buy	+34	New	+$72.9K	﹤0.01%	12838

Other funds holding INM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $431M AUM 20.62% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Citadel Advisors's INM Position: Q1 2026 in Review

Citadel Advisors opened a new position in InMed Pharmaceuticals (INM) in Q1 2026: 46,973 shares worth $30.3K. The stake represents ﹤0.01% of the portfolio and ranks #12568 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INM as recently as Q3 2024.

Citadel Advisors first reported a position in INM in Q1 2021 and has held it in 10 quarters since. The position peaked at $57K in Q1 2021. 9 funds tracked by Wall St. Rank hold INM as of Q1 2026.

Citadel Advisors held 46,973 shares of InMed Pharmaceuticals worth $30.3K as of Q1 2026.
InMed Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
InMed Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12568 holding.
Citadel Advisors first reported a position in InMed Pharmaceuticals in Q1 2021 and has held it in 10 quarters since.
Citadel Advisors's InMed Pharmaceuticals position peaked at $57K in Q1 2021.
9 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.